COCOMO-ACS Study: The Colchicine for coronary plaque modification in Acute Coronary Syndrome Study

COCOMO-ACS was a double-blind, placebo-controlled trial that randomized 64 patients (median age 61.5 years; 9.4% female) with acute non-ST-segment elevation MI to colchicine 0.5 mg daily or placebo for a median of 17.8 months in addition to guideline-recommended therapy. Participants underwent serial OCT imaging within a matched segment of non-culprit coronary artery that contained at least one lipid-rich plaque causing ≥20% stenosis. The primary outcome was the change in minimum fibrous cap thickness (FCT) in non-culprit segments from baseline to final visit.

COCOMO-ACS是一项双盲、安慰剂对照临床试验，将64例中位年龄为61.5岁、女性占比9.4%的急性非ST段抬高型心肌梗死（acute non-ST-segment elevation MI）患者随机分为两组，在接受指南推荐治疗方案的基础上，分别予以每日0.5mg秋水仙碱或安慰剂治疗，中位随访时长为17.8个月。受试者需在包含至少一处导致狭窄程度≥20%的富脂质斑块的非罪犯冠状动脉（non-culprit coronary artery）匹配节段内，接受系列光学相干断层成像（optical coherence tomography, OCT）检查。本试验的主要结局为：非罪犯冠状动脉节段的最小纤维帽厚度（fibrous cap thickness, FCT）从基线至末次随访的变化值。